dystrophin

Sarepta Therapeutics Inc (NASDAQ: SRPT) was up 28.97 percent after the FDA requested Dystrophin data prior to making a decision on Eteplirsen NDA in addition to Wedbush upgrading the company to Outperform with a price target of $36.00. United Natural Foods, Inc. (NASDAQ: UNFI) rose 10.74 percent...

The FDA has requested Sarepta Therapeutics Inc (NASDAQ: SRPT) for dystrophin data in the ongoing evaluation of the eteplirsen New Drug Application [NDA]. Wedbush’s Heather Behanna upgraded the rating for the company from Neutral to Outperform, while raising the price target from $14 to $36...